title: PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
abstract: Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. Clin Cancer Res; 22(18); 4539-41. ©2016 AACRSee related article by Gainor et al., p. 4585.
authors.affiliation: Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut. Scott.Gettinger@yale.edu.
authors.forename: Scott
authors.initials: S
authors.lastname: Gettinger
authors.affiliation: Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.
authors.forename: Katerina
authors.initials: K
authors.lastname: Politi
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D058990:Molecular Targeted Therapy; D009154:Mutation; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D059016:Tumor Microenvironment / Q000187:drug effects / Q000235:genetics / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases